L&C Bio Co. Ltd (290650) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.014x

Based on the latest financial reports, L&C Bio Co. Ltd (290650) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.79 Billion ≈ $2.57 Million USD) by net assets (₩266.71 Billion ≈ $180.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See L&C Bio Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

L&C Bio Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how L&C Bio Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

L&C Bio Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of L&C Bio Co. Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
IReader Technology Co Ltd
SHG:603533
-0.031x
Shanghai Geoharbour Construction Group Co Ltd
SHG:605598
0.032x
Develia S.A
WAR:DVL
0.028x
Navigator Holdings Ltd
NYSE:NVGS
0.038x
Derichebourg
PA:DBG
0.205x
Ls Cable & System Asia Ltd
KO:229640
0.011x
Sunac China Holdings Limited
F:SCNR
-0.097x
Xiamen Jihong Package Technology Ltd
SHE:002803
-0.014x

Annual Cash Flow Conversion Efficiency for L&C Bio Co. Ltd (2015–2024)

The table below shows the annual cash flow conversion efficiency of L&C Bio Co. Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 290650 stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩284.35 Billion
≈ $192.70 Million
₩-8.57 Billion
≈ $-5.81 Million
-0.030x +63.51%
2023-12-31 ₩146.94 Billion
≈ $99.58 Million
₩-12.13 Billion
≈ $-8.22 Million
-0.083x -33.11%
2022-12-31 ₩97.95 Billion
≈ $66.38 Million
₩-6.08 Billion
≈ $-4.12 Million
-0.062x -148.35%
2021-12-31 ₩85.02 Billion
≈ $57.62 Million
₩10.91 Billion
≈ $7.39 Million
0.128x -0.05%
2020-12-31 ₩57.81 Billion
≈ $39.17 Million
₩7.42 Billion
≈ $5.03 Million
0.128x +16.12%
2019-12-31 ₩58.18 Billion
≈ $39.43 Million
₩6.43 Billion
≈ $4.36 Million
0.111x +50.78%
2018-12-31 ₩52.46 Billion
≈ $35.55 Million
₩3.85 Billion
≈ $2.61 Million
0.073x -67.72%
2017-12-31 ₩16.81 Billion
≈ $11.39 Million
₩3.82 Billion
≈ $2.59 Million
0.227x +1327.62%
2016-12-31 ₩10.02 Billion
≈ $6.79 Million
₩-185.35 Million
≈ $-125.61K
-0.018x +94.55%
2015-12-31 ₩3.91 Billion
≈ $2.65 Million
₩-1.33 Billion
≈ $-899.78K
-0.339x --

About L&C Bio Co. Ltd

KQ:290650 Korea Medical Devices
Market Cap
$1.34 Billion
₩1.97 Trillion KRW
Market Cap Rank
#7832 Global
#210 in Korea
Share Price
₩80200.00
Change (1 day)
-7.07%
52-Week Range
₩26800.00 - ₩118300.00
All Time High
₩118300.00
About

L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.